ProShare Advisors
NBRV

ProShare Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

ProShare Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-108
Closed -$73K – 1767
2018
Q3 		$73K Buy
108
+40
+59% +$28.4K ﹤0.01% 1705
2018
Q2 		$59K Hold
68
– – ﹤0.01% 1743
2018
Q1 		$85K Sell
68
-11
-14% -$16.3K ﹤0.01% 1652
2017
Q4 		$118K Buy
+79
New +$125K ﹤0.01% 1721

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ProShare Advisors's NBRV Position: Q4 2018 in Review

ProShare Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2018, closing a stake of 108 shares — an estimated $73K sold.

ProShare Advisors first reported a position in NBRV in Q4 2017 and held it in 4 quarters. The position peaked at $118K in Q4 2017. 47 funds tracked by Wall St. Rank hold NBRV as of Q4 2018.

  • ProShare Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2018 after selling out during the quarter.
  • ProShare Advisors sold 108 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2018, an estimated $73K.
  • ProShare Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 4 quarters.
  • ProShare Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $118K in Q4 2017.
  • 47 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2018.

Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.